{"id":"W4281764145","doi":"10.1200/jco.2022.40.16_suppl.tps9137","title":"Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; non-small cell lung cancer (NSCLC); Trastuzumab; KRAS; Metastatic breast cancer; Phases of clinical research; Cancer; Lung cancer; Clinical trial; Breast cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002034603,0.001560036,0.001948535,0.0003516698,0.0004706523,0.001549072,0.001068412,0.0016952,0.004844603],"category_scores_gemma":[0.001405109,0.0007120398,0.001396859,0.0004834569,0.001239102,0.001360175,0.0004024401,0.003477064,0.001111315],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001446601,"about_ca_system_score_gemma":0.001922278,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001543566,"about_ca_topic_score_gemma":0.004916047,"domain_scores_codex":[0.9994615,0.0002747977,0.00002002156,0.0001041678,0.00004096191,0.00009862198],"domain_scores_gemma":[0.9989821,0.0001886553,0.0002154001,0.00008181072,0.00006730054,0.0004646639],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9278293,0.03273612,0.002561487,0.0003567049,0.0009223914,0.00009364698,0.0001409274,0.0009196545,0.008076136,0.000181342,0.002041481,0.02414089],"study_design_scores_gemma":[0.8530015,0.1404177,0.003533278,0.00001940402,0.0002590961,0.00007706467,0.00004176477,0.0007134591,0.0006806995,0.0001703035,0.001069131,0.00001654606],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986259,0.002552294,0.0008448393,0.0006632223,0.0003763148,0.005194474,0.001776041,0.0001496187,0.002184135],"genre_scores_gemma":[0.9843965,0.001940773,0.002065091,0.001540277,0.0002968718,0.004216715,0.002450234,0.0000451954,0.003048208],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004844603,"threshold_uncertainty_score":0.0162068,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2405047673885687,"score_gpt":0.5669676579238045,"score_spread":0.3264628905352358,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}